Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/23481
Title: Optimal oral cyclosporin dosing with concomitant posaconazole post allogeneic stem cell transplantation.
Authors: Robinson, Danielle H;Hughes, Charlotte F M;Grigg, Andrew P
Affiliation: Department of Clinical Haematology, Austin Health, Heidelberg, Victoria, Australia
Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, Victoria, Australia
Issue Date: 30-May-2020
EDate: 2020-05-30
Citation: Leukemia & lymphoma 2020; online first: 30 May
Abstract: Cyclosporin is an immunosuppressive agent in allogeneic hematopoietic stem cell transplantation and its metabolism is strongly affected by concomitant drugs, including posaconazole which is now extensively used as anti-fungal prophylaxis post-allograft. We undertook a retrospective audit of 29 patients undergoing their first allograft who were receiving posaconazole at the time of transition from intravenous to oral cyclosporin. This group had a median initial oral cyclosporin dose of 2.58 mg/kg bd (range 1.75-3.95) and high incidence of cyclosporin-related toxicity was noted, requiring significant dose reductions such that by day 60 the media dose was 1.60 mg/kg bd (range 0.86-3.33). We subsequently amended our dosing protocol and analyzed a further 20 patients specifying an initial oral cyclosporin dose of 2.25 mg/kg bd and found this had little impact on toxicity or requirement for dose reductions. Starting doses of no greater than 2 mg/kg bd appear optimal to prevent toxicity in allograft recipients receiving concomitant posaconazole.
URI: http://ahro.austin.org.au/austinjspui/handle/1/23481
DOI: 10.1080/10428194.2020.1768381
ORCID: 0000-0003-0384-704X
0000-0001-9809-6757
PubMed URL: 32476517
Type: Journal Article
Subjects: Transplantation
cyclosporin
drug toxicity
posaconazole
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.